A contemporary approach to the diagnosis and management of polycythemia vera
- PMID: 12901345
A contemporary approach to the diagnosis and management of polycythemia vera
Abstract
The natural history of polycythemia vera (PV) includes an increased lifetime risk of thrombohemorrhagic complications and disease transformation into myelofibrosis with myeloid metaplasia and acute myeloid leukemia. The latter is the primary reason for the shortening of survival that becomes significant after the first decade of disease. Historic nonrandomized studies have suggested that aggressive phlebotomy improves survival in PV. However, prospective randomized studies have failed to demonstrate a better treatment than phlebotomy alone, in terms of survival. However, the addition of cytoreductive therapy to phlebotomy in high-risk patients with PV may reduce the risk of recurrent thrombosis. Other disease features of PV include aquagenic pruritus and microvascular disturbances such as erythromelalgia. This review outlines a practical approach to diagnosis, in addition to treatment of life-threatening and non-life-threatening complications of PV.
Similar articles
-
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.Am J Hematol. 2012 Mar;87(3):285-93. doi: 10.1002/ajh.23135. Am J Hematol. 2012. PMID: 22331582 Review.
-
Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.Am J Hematol. 2013 Jun;88(6):507-16. doi: 10.1002/ajh.23417. Am J Hematol. 2013. PMID: 23695894
-
Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Am J Hematol. 2011 Mar;86(3):292-301. doi: 10.1002/ajh.21946. Am J Hematol. 2011. PMID: 21351120 Review.
-
Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.Semin Thromb Hemost. 2006 Apr;32(3):174-207. doi: 10.1055/s-2006-939431. Semin Thromb Hemost. 2006. PMID: 16673274 Review.
-
Evidence-based management of polycythemia vera.Best Pract Res Clin Haematol. 2006;19(3):483-93. doi: 10.1016/j.beha.2005.07.007. Best Pract Res Clin Haematol. 2006. PMID: 16781485 Review.
Cited by
-
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.Curr Hematol Malig Rep. 2006 Jun;1(2):69-74. doi: 10.1007/s11899-006-0025-4. Curr Hematol Malig Rep. 2006. PMID: 20425334 Review.
-
Polycythaemia vera and essential thrombocythaemia: current treatment strategies.Drugs. 2006;66(17):2173-87. doi: 10.2165/00003495-200666170-00003. Drugs. 2006. PMID: 17137402 Review.
-
The effects of size and period of administration of gold nanoparticles on rheological parameters of blood plasma of rats over a wide range of shear rates: in vivo.Lipids Health Dis. 2011 Oct 27;10:191. doi: 10.1186/1476-511X-10-191. Lipids Health Dis. 2011. PMID: 22032228 Free PMC article.